Daniel J. Blackman

Showing 1-7 of 7 articles

Interventions for valvular disease

Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients

Meredith I, Dumonteil N, Blackman D, Tchétché D, Walters D, Hildick-Smith D, Manoharan G, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Feldman T, Allocco D, Dawkins K

September 20, 2017 | 10.4244/EIJ-D-16-01024

Interventions for valvular disease

Insights into the need for permanent pacemaker following implantation of the repositionable LOTUS valve for transcatheter aortic valve replacement in 250 patients: results from the REPRISE II trial with extended cohort

Dumonteil N, Meredith I, Blackman D, Tchétché D, Hildick-Smith D, Spence M, Walters D, Harnek J, Worthley S, Rioufol G, Lefèvre T, Modine T, Van Mieghem N, Houle V, Allocco D, Dawkins K

September 20, 2017 | 10.4244/EIJ-D-16-01025

Coronary interventions

Post-procedural myocardial infarction following surgical aortic valve replacement and transcatheter aortic valve implantation

Dobson L, Musa T, Uddin A, Fairbairn T, Swoboda P, Ripley D, Garg P, Evans B, Malkin C, Blackman D, Plein S, Greenwood J

June 2, 2017 | 10.4244/EIJ-D-16-00558

Interventions for valvular disease

Impact of left ventricular function and transaortic gradient on outcomes from transcatheter aortic valve implantation: data from the UK TAVI Registry

Malkin C, Long W, Baxter P, Gale C, Wendler O, Monaghan M, Thomas M, Ludman P, De Belder M, Cunningham A, Moat N, Blackman D

February 19, 2016 | 10.4244/EIJY14M12_12

Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population

Shelton R, Eftychiou C, Somers K, Liu A, Burton-Wood N, Anderson M, Makri L, Blaxill J, McLenachan J, Wheatcroft S, Greenwood J, Blackman D

May 21, 2013 | 10.4244/EIJV9I1A17

Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design

Kelly D, McCann G, Blackman D, Curzen N, Dalby M, Greenwood J, Fairbrother K, Shipley L, Kelion A, Heatherington S, Khan J, Nazir S, Alahmar A, Flather M, Swanton H, Schofield P, Gunning M, Hall R, Gershlick A

February 22, 2013 | 10.4244/EIJV8I10A183

Complications of transcatheter aortic valve implantation: avoidance and management

Hildick-Smith D, Redwood S, Mullen M, Thomas M, Kovac J, Brecker S, Trivedi U, Young C, Hutchinson N, MacCarthy P, Prendergast B, De Belder M, Monaghan M, Blackman D, Baumbach A, Manoharan G, Moat N

September 30, 2011 | 10.4244/EIJV7I5A99

1

Latest news

Percutaneous management of left ventricular assist device outflow graft obstruction

FREE ARTICLE - Aleksandra Gasecka et al.

January 19, 2022

Lipid-rich plaque density and LDL-C in statin-treated vs statin-naïve patients

FREE ARTICLE - Rebecca Torguson et al.

January 17, 2022

EuroCTO Club Consensus on Dual Lumen Microcatheters for CTO Recanalisation; Predicting Radial Crossover in ACS, the MATRIX score; DAPT duration for BRS; and more…

December 17, 2021

Redo transcatheter mitral valve replacement in mitral annular calcification

FREE ARTICLE - Jennifer Jdaidani et al

January 13, 2022

TAVI vs SAVR in bicuspid aortic valve stenosis

FREE ARTICLE - Monil Majmundar et al.

January 12, 2022

Management of MR patients undergoing TMVI screening

FREE ARTICLE - Sebastian Ludwig et al.

January 7, 2022

Outcomes in patients with ACS treated with the NeVa stent

FREE ARTICLE - Alessandro Spirito et al.

January 7, 2022

Valvular disease